Docoh
Loading...

EYPT EyePoint Pharmaceuticals

News

From Benzinga Pro
EyePoint Pharma Highlights Presentation Of Prelim. Data From Phase 1 DAVIO Trial, YUTIQ CALM Registry Study At American Society Of Retina Specialists Meeting
12 Oct 21
Biotech, News, FDA, General
– 3-month safety data from DAVIO trial continues to demonstrate EYP-1901 is well-tolerated in eyes with wet AMD – – YUTIQ® CALM registry study collecting real-world data on patients with
EyePoint Pharma Sponsored Study Titled 'A study to evaluate the safety and efficacy of an FAI insert for the management of subjects with non-infectious uveitis affecting the posterior segment of the eye' Posted To ClinicalTrials.gov
7 Oct 21
Biotech, News, FDA, General
https://clinicaltrials.gov/ct2/show/NCT05070728
EyePoint Sets its Sights on Developing Treatments Improving the Lives of Eye Disease Sufferers
30 Sep 21
Biotech, News, Health Care, Small Cap, Markets, General
Photo Credit: EyePoint Pharmaceuticals
EyePoint Pharma Reports Will Present Data At American Academy Of Ophthalmology Meeting
17 Sep 21
Biotech, News, FDA, General
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that a
EyePoint Sets its Sights on Continued Trial Success in Developing Treatments Improving the Lives of Eye Disorder Sufferers
14 Sep 21
Biotech, News, Health Care, General
Photo by Brands&People on Unsplash
EyePoint Pharmaceuticals Q2 EPS $(0.35) Beats $(0.43) Estimate, Sales $8.70M Miss $9.13M Estimate
4 Aug 21
Earnings, News
EyePoint Pharmaceuticals (NASDAQ:EYPT) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.43) by 18.6 percent. This is a 250 percent decrease over losses of $(0.10) per share
Earnings Scheduled For August 4, 2021
4 Aug 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • UroGen Pharma (NASDAQ:URGN) is projected to report earnings for its second quarter.